Skip to content

Tolerance and Potential Synergistic Effect of the Combination of Intranasal Esketamine and Non-selective MAOI

Tolerance and Potential Synergistic Effect of the Combination of Intranasal Esketamine and Non-selective Monoamine Oxidase Inhibitors (MAOIs)

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05530668
Acronym
ESKETAM
Enrollment
13
Registered
2022-09-07
Start date
2022-04-11
Completion date
2022-12-11
Last updated
2023-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression Anxiety Disorder

Keywords

Depression Disorder, Anxiety Disorder, intranasal esketamine, monoamine oxidase inhibitors (MAOIs), MAOIs, antidepressants, ketamine

Brief summary

There are already recently published data on the tolerability and efficacy of the combination of ketamine and/or esketamine with MAOIs. However, these reports are few and far between, and to our knowledge, there are no data involving intranasal esketamine. Given the numerous interactions between MAOIs and other antidepressants, and the impossibility of combination, this pharmacological class is neglected. This is despite the fact that MAOIs are the only truly tri-aminergic drugs, that they have unparalleled efficacy in certain forms of resistant apathetic depression, and that new, more dietary permissive forms have appeared on the market. The arrival of antidepressants that can be combined with MAOIs, such as ketamine and esketamine, changes the situation and could offer a new treatment opportunity to many patients in a therapeutic impasse. For these opportunities to become a reality, sharing the clinical experience gained by specialized centers is essential.

Interventions

None listed

Sponsors

University Hospital, Strasbourg, France
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

* Major subject. * Having been treated with intranasal esketamine between 01/01/2018 and 01/03/2022. * Not objecting to the reuse of their data for scientific research purposes.

Exclusion criteria

\- Subject who has expressed opposition to the reuse of their data for scientific research purposes.

Design outcomes

Primary

MeasureTime frame
Number of adverse events for each patientFiles analysed retrospectively from January 01, 2018 to March 31, 2022 will be examined

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026